Sakaida Emiko, Nakaseko Chiaki, Harima Akane, Yokota Akira, Cho Ryuko, Saito Yasushi, Nishimura Miki
Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, Chiba City, Chiba, 260-8670, Japan.
Blood. 2003 Dec 1;102(12):4236-42. doi: 10.1182/blood-2002-10-3289. Epub 2003 Aug 7.
Late-onset noninfectious pulmonary complications (LONIPCs) occurring beyond 3 months after allogeneic stem cell transplantation (allo-SCT) have become recognized as life-threatening complications, and they reduce the recipient's quality of life. However, the pathogenesis and optimal treatment for LONIPCs are still unclear. In this study, we retrospectively analyzed the incidence and outcome of LONIPCs among allo-SCT recipients. Between October 1993 and September 2001, 96 patients underwent allo-SCT and 76 patients who survived and were free of disease for more than 3 months after SCT were enrolled. Among the 76 patients, 18 patients (23.7%) developed LONIPCs at a median interval of 227 days after allo-SCT (range, 91-1105 days). The patients with LONIPCs were subclassified into those with bronchiolitis obliterans (BO) (6 patients), with interstitial pneumonia (IP) (11 patients), or with both BO and IP (1 patient). The presence of extensive chronic graft-versus-host disease (GVHD) was significantly associated with the development of LONIPCs (P =.0008). Liver or skin involvement in chronic GVHD was not associated, but sicca syndrome was significantly associated with the development of LONIPCs (P <.0001). Most of the IP patients (58.3%) responded well to immunosuppressive treatment, while BO patients did not respond to the therapy. Eight of the 18 patients with LONIPCs died. The major cause of death was respiratory failure (62.5%). The relapse rate of primary malignant disease in the LONIPC patients was significantly lower than that of non-LONIPC patients (1 of 17 [5.9%] versus 16 of 52 [30.8%]; P =.0387). These results indicate that the development of LONIPCs was strongly associated with chronic GVHD and especially with sicca syndrome and the graft-versus-leukemia (GVL) effect.
异基因造血干细胞移植(allo-SCT)3个月后发生的迟发性非感染性肺部并发症(LONIPCs)已被公认为危及生命的并发症,会降低受者的生活质量。然而,LONIPCs的发病机制和最佳治疗方法仍不清楚。在本研究中,我们回顾性分析了allo-SCT受者中LONIPCs的发生率和转归。1993年10月至2001年9月期间,96例患者接受了allo-SCT,76例存活且在SCT后3个月以上无疾病的患者被纳入研究。在这76例患者中,18例(23.7%)在allo-SCT后中位间隔227天(范围91 - 1105天)发生了LONIPCs。发生LONIPCs的患者被细分为闭塞性细支气管炎(BO)患者(6例)、间质性肺炎(IP)患者(11例)或同时患有BO和IP的患者(1例)。广泛慢性移植物抗宿主病(GVHD)的存在与LONIPCs的发生显著相关(P = 0.0008)。慢性GVHD累及肝脏或皮肤与之无关,但干燥综合征与LONIPCs的发生显著相关(P < 0.0001)。大多数IP患者(58.3%)对免疫抑制治疗反应良好,而BO患者对该治疗无反应。18例LONIPCs患者中有8例死亡。主要死亡原因是呼吸衰竭(62.5%)。LONIPCs患者原发性恶性疾病的复发率显著低于非LONIPCs患者(17例中的1例[5.9%]对52例中的16例[30.8%];P = 0.0387)。这些结果表明,LONIPCs的发生与慢性GVHD密切相关,尤其是与干燥综合征和移植物抗白血病(GVL)效应有关。